Older Adults Prescribed Cannabis in UK Show Self-Reported Well-Being Gains, But Study Design Cannot Confirm Treatment Caused Improvement

Registry data from the UK’s T21 project describes a distinct older patient profile, with more women, more pain indications, and less THC exposure, but the absence of a control group means the reported improvements in well-being cannot be reliably attributed to cannabis treatment itself.

Why This Matters

Adults aged 65 and older are among the fastest-growing segments of the medical cannabis user population worldwide, yet clinical trials have almost systematically excluded them. This means prescribers are making decisions for older patients based largely on data drawn from younger adults with different conditions, different drug metabolism, and different risk profiles. Real-world registry data from this age group, even when limited by design, can begin to fill that gap by characterizing who these patients are and what patterns emerge in their care. The timing matters because regulatory frameworks in the UK and elsewhere are evolving rapidly, and the absence of age-specific evidence leaves both clinicians and patients without adequate guidance.

Clinical Summary

Chronic pain, insomnia, and mood disturbance are disproportionately common in older adults, and conventional pharmacological options often carry significant risks in this population, including polypharmacy interactions, falls, and cognitive impairment. Against this backdrop, a team of researchers in the United Kingdom analyzed data from the T21 registry, a multi-centre prospective observational registry of patients prescribed cannabis-based medicinal products (CBMPs) through private-sector telemedicine clinics. Published in Expert Review of Neurotherapeutics, the study compared adults aged 65 and older with those under 65, examining demographics, prescribing patterns, and self-reported well-being at baseline and three-month follow-up. The mechanistic basis for potential benefit rests on the endocannabinoid system’s role in pain modulation, sleep regulation, and mood, though these pathways are better characterized in preclinical and younger adult populations than in older cohorts.

The registry enrolled 4,228 patients at baseline, of whom just 198 (4.7%) were aged 65 or older. Older adults were more likely to be female, to seek treatment for pain, and to receive lower-THC, CBD-dominant oil formulations. Over three months, statistically significant improvements were reported across all four self-reported well-being domains (quality of life, general health, mood, and sleep) in both age groups, though sleep improvements were less pronounced in older adults. However, the study had no control or placebo group, attrition exceeded 42% overall and approached 50% in the older subgroup, and all outcomes were self-reported. The authors themselves acknowledge that these improvements cannot be causally attributed to CBMPs and that randomized controlled trials in older adults are needed before clinical recommendations can be drawn.

Dr. Caplan’s Take

What this study does well is put a face on the older patient seeking prescribed cannabis in the UK: more likely to be a woman in her late sixties or seventies, dealing with chronic pain, often cannabis-naive, and receiving conservative, CBD-leaning prescriptions. That descriptive picture is useful and rings true with what I see in practice. But the leap from “patients reported feeling better after three months” to “cannabis worked” is exactly the kind of inference this study cannot support. Patients who self-select into private-pay cannabis programs and then remain enrolled long enough to complete follow-up questionnaires are not a representative sample, and without a comparator arm, regression to the mean and placebo effects are perfectly plausible explanations for every improvement reported.

When an older patient asks me about cannabis for chronic pain, I am honest: the evidence base specific to their age group is thin. What I do is evaluate their full medication list, assess fall risk and cognitive baseline, start low with CBD-dominant formulations if we proceed, and monitor closely. I treat the registry data as what it is: a reason to keep investigating, not a reason to prescribe with confidence.

Clinical Perspective

This study sits early in the research arc for cannabis use in older adults, contributing descriptive characterization rather than efficacy evidence. It confirms what smaller case series and survey data have suggested: that older patients who seek prescribed cannabis tend to present with pain, receive more conservative formulations, and have less prior cannabis experience. What it does not and cannot confirm is that the reported improvements in quality of life, mood, general health, or sleep are attributable to the prescribed products. For patient-facing conversations, clinicians can draw on the demographic and prescribing profile data to inform expectations, but should not cite these outcomes as evidence that CBMPs are effective in this population.

From a pharmacological standpoint, older adults warrant particular caution with any cannabis-based product. Age-related changes in hepatic metabolism, renal clearance, body composition, and blood-brain barrier permeability can all amplify both therapeutic and adverse effects. THC in particular raises concerns about cognitive impairment, orthostatic hypotension, and falls in a population already at elevated risk. Drug interactions with anticoagulants, antihypertensives, and CNS depressants are clinically relevant and underexplored. The most actionable step a clinician can take now is to ensure that any older patient considering medical cannabis receives a thorough medication reconciliation and a structured monitoring plan, with low starting doses and slow titration, rather than relying on registry-level outcome data to guide dosing decisions.

Study at a Glance

Study Type

Prospective observational registry (T21), pre-post and cross-sectional age-group comparison

Population

UK adults prescribed cannabis via private telemedicine clinics; 198 aged 65+ and 4,030 aged under 65 at baseline

Intervention

Prescribed cannabis-based medicinal products including CBD-dominant oils and THC-dominant flower

Comparator

Within-person pre-post comparison; cross-sectional comparison between age groups

Primary Outcomes

EQ-5D-5L (quality of life), EQ-5D VAS (general health), PHQ-9 (mood/depression), Pittsburgh Sleep Quality Index-derived items (sleep)

Sample Size

4,228 at baseline; 2,455 at 3-month follow-up (98 aged 65+)

Journal

Expert Review of Neurotherapeutics

Year

2024

DOI or PMID

Not provided in source data

Funding Source

T21 registry established by Drug Science, which partners commercially with licensed cannabis producers

What Kind of Evidence Is This

This is an original research article reporting data from a prospective observational patient registry. In the evidence hierarchy, observational registry studies sit well below randomized controlled trials and systematic reviews. The single most important inference constraint this design imposes is the absence of a control group: without randomization and a comparator condition, it is impossible to determine whether observed pre-to-post changes were caused by the intervention, by placebo response, by regression to the mean, by natural disease fluctuation, or by the selective retention of patients who happened to improve.

How This Fits With the Broader Literature

The descriptive finding that older cannabis patients are more likely to be female, pain-focused, and prescribed conservative formulations aligns with survey data from Israel, Canada, and the United States, where similar demographic patterns have been reported in studies of older medical cannabis users. The pre-to-post improvements in well-being echo findings from other T21 registry analyses across conditions such as chronic pain and anxiety, though those analyses share the same fundamental design limitations. What this study adds is a UK-specific, age-stratified snapshot within a regulatory context where medical cannabis remains primarily accessible through private-pay channels, potentially limiting generalizability even within the UK population.

Notably absent from the broader literature are adequately powered randomized controlled trials of cannabis-based products in adults over 65 for any indication. Until such trials are conducted, the field remains dependent on observational data that can characterize patient profiles and generate hypotheses but cannot establish efficacy or safety with confidence.

Common Misreadings

The most likely overinterpretation is reading this study as evidence that medical cannabis is effective for improving quality of life, mood, health, and sleep in older adults. The authors’ own language, including terms such as “improvements” and “effectiveness,” can inadvertently encourage this reading. However, the study design, with no placebo or active comparator, high attrition that likely favored retention of satisfied patients, and exclusively self-reported outcomes, does not support causal claims. A patient who stayed in a private-pay program and completed a three-month questionnaire is not equivalent to a patient randomized to treatment in a blinded trial. The statistically significant p-values reflect within-group change in a self-selected, partially retained sample and should not be mistaken for evidence of treatment efficacy.

Bottom Line

This registry study provides a useful descriptive portrait of older UK adults who seek prescribed cannabis: predominantly women with chronic pain, receiving conservative CBD-leaning formulations, and largely cannabis-naive. The pre-to-post improvements in self-reported well-being are documented but not interpretable as treatment effects given the absence of a control group and substantial loss to follow-up. For clinical practice, the value lies in the demographic and prescribing characterization, not in outcome data. Randomized controlled trials in this age group remain the critical unmet need.

References

1. T21 Registry analysis of cannabis-based medicinal products in older adults aged 65 and over. Expert Review of Neurotherapeutics, 2024. (Primary study; DOI not provided in source data.)
2. Abuhasira R, Schleider LB, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. European Journal of Internal Medicine. 2018;49:44-50.
3. Minerbi A, Bhatt S, Engert L, et al. Medical cannabis for older patients: A qualitative study. Drugs & Aging. 2021;38(11):995-1005.
4. Kvamme SL, Pedersen MM, Alagem-Iversen S, Thylstrup B. Beyond the high: Mapping patterns of use and motives for use of cannabis as medicine. Nordic Studies on Alcohol and Drugs. 2021;38(3):270-292.